GeneNews selected to present late-breaking abstract at AACR Annual Meeting

    -Abstract describes six-gene biomarker panel for assessment of current
    risk for colorectal cancer-

    TORONTO, March 17 /CNW/ - GeneNews Limited (TSX: GEN), a company focused
on developing molecular diagnostic tests derived from a simple blood sample
for the early detection of diseases and personalized health management, today
announced that its abstract describing the performance of the Company's
six-gene biomarker panel for the assessment of a person's current risk for
colorectal cancer from a blood sample, has been selected for presentation at
the American Association for Cancer Research (AACR) Annual Meeting held from
April 12-16, 2008 in San Diego, California. The abstract is entitled
"Stratification of colorectal cancer probability using six genes from whole
    "This six gene biomarker set will form the basis of a laboratory
developed test (LDT) version of ColonSentry(TM), which we expect to launch in
the third quarter of 2008 through our in-house clinical reference lab located
in the Toronto-area," said K. Wayne Marshall, MD, PhD, President and Chief
Executive Officer of GeneNews. "We are pleased that AACR has chosen to accept
our abstract given the limited number of late-breaking submissions that are
accepted and believe that this acceptance also represents further
peer-reviewed validation of our proprietary Sentinel Principle technology."

    The following GeneNews abstract will be presented:

    Abstract Number LB-214:
    "Stratification of colorectal cancer probability using six genes from
whole blood." Clinical Research 2, Poster Section 19, Tuesday, April 15, 2008,
8:00 AM

    About GeneNews
    GeneNews is focused on the application of functional genomics to enable
early diagnosis and personalized therapeutic intervention based on
disease-specific biomarkers. The Company has developed a novel approach, the
Sentinel Principle(TM), to detect and stage virtually any disease or medical
condition from a simple blood sample. GeneNews is currently applying the
Sentinel Principle in major areas with unmet clinical needs such as cancer,
arthritis, cardiovascular disease and neurological disorders. GeneNews' first
product in development, ColonSentry, is a convenient and patient-friendly
blood-based biomarker test that can identify the current risk of colorectal
cancer. For more information on GeneNews, visit

    This press release contains forward-looking statements, which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual events could differ
materially from those projected herein. Investors should consult the Company's
ongoing quarterly filings and annual reports for additional information on
risks and uncertainties relating to these forward-looking statements. The
reader is cautioned not to rely on these forward-looking statements. The
Company disclaims any obligation to update these forward-looking statements.

    %SEDAR: 00009903E

For further information:

For further information: James Smith, (416) 815-0700 x 229,

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890